2017, Vol. 30
2. Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China;
3. Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Biobank for Clinical Data and Samples in Pediatric, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
Objective To characterize carbapenem (CPM)-non-susceptible Klebsiella pneumoniae (K. pneumoniae) and carbape-nemase produced by these strains isolated from Beijing Children's Hospital based on a five-year surveillance.
Methods The Minimal Inhibition Concentration values for 15 antibiotics were assessed using the Phonix100 compact system. PCR amplification and DNA sequencing were used to detect genes encoding carbapenemases. WHONET 5.6 was finally used for resistance analysis.
Results In total, 179 strains of CPM-non-susceptible K. pneumoniae were isolated from January, 2010 to December, 2014. The rates of non-susceptible to imipenem and meropenem were 95.0% and 95.6%, respectively. In the 179 strains, 95 (53.1%) strains carried the blaIMP gene, and IMP-4 and IMP-8 were detected in 92 (96.8%) and 3 (3.2%) IMP-producing isolates, respectively. 65 (36.3%) strains carried the blaNDM-1 gene. 6 (3.4%) strains carried the blaKPC gene, and KPC-2 were detected in 6 KPC-producing isolates. In addition, New Delhi-Metallo-1 (NDM-1) producing isolates increased from 7.1% to 63.0% in five years and IMP-4 producing isolates decreased from 75.0% to 28.3%.
Conclusion High frequencies of multiple resistances to antibiotics were observed in the CPM-non-susceptible K. pneumoniae strains isolated from Beijing Children's Hospital. The production of IMP-4 and NDM-1 metallo-β-lactamases appears to be an important mechanism for CPM-non-susceptible in K. pneumoniae.
Klebsiella pneumoniae (K. pneumoniae) is a common opportunistic pathogen of community and healthcare associated infections[1]. Multidrug-resistant K. pneumoniaeis spreading globally and producing serious infections associated with septicemia, pnumonia, urinarytract infection, intra-abdominal infection, and bacterial meningitis[2]. However, there are very limited therapeutic options available for multidrug-resistant K. pneumoniae, causing an unprecedented public health crisis[2-3].
As a useful therapeutic agent, carbapenems (CPMs) play an important role in treating infections of multidrug-resistant K. pneumoniae, particularly those carrying genes for extended-spectrumβ-lactamases[4]. However, with therapeutic use of CPMs in hospitals, CPM-resistant K. pneumoniae has also been emergent and increased rapidly[5-6]. Resistance to CPMs of K. pneumoniae typically involves several mechanisms, and the production of carbapenemases (CPMases) is an important one[7-9]. Besides CPM, CPMases can also hydrolyze the majority of β-lactam antibiotics, including penicillins, cephalosporins and cephamycins. Traditionally, CPMases have been assigned to Ambler classes A (KPC-type), B (MBL), and D (OXA-type)[2, 10]. The CPMases were encoded by CPMase-producing genes, such as blaIMP, blaVIM, blaKPC[2].
Recently, spread of CPMase-producing K. pneumoniae has been reported worldwide, and the phenotypic and genotypic characteristics of the strains from many countries have been identified[2, 8-9]. However, the phenotypic and genotypic studies on clinical isolates of CPMase-producing K. pneumoniae in China were very few and all of these investigations were performed in a very short period[11-13]. Herein, we conducted a five-year surveillance of CPMase-producing K. pneumoniae in one of the most famous children's hospitals of China, to reveal both phenotypic and genotypic characteristics of clinical isolates of CPMase-producing K. pneumoniae from pediatric patients between 2010 and 2014. Our results demonstrated that a more resistant genotypic subtype, namely New Delhi-Metallo-1 (NDM-1), were gradually increasing and becoming predominant in the pediatric patients, which deserved the attention of both pediatricians and public health officials.
Materials and Methods Settings and PatientsBeijing Children's Hospital, Capital Medical University, is a general pediatric teaching hospital with 970 beds. The hospital has more than 70, 000 admissions per year. All the patients were recruited as inpatients in Beijing Children's Hospital from January 2010 to December 2014.
Bacterial Strains1, 730 strains of K. pneumoniae were isolated from nasopharyngeal secretions, tracheal aspirations, blood, pus secretions, mid-stream catheterized urine, pleural effusions, catheter and ascites. Routine methods and the Phoenix100 automated microbiology analyzer (BD Research Inc. USA) were employed to identify the bacterial strains.
Screening of CPM Non-susceptible StrainsThe CPM-non-susceptible isolates of K. pneumoniae were identified by disk diffusion method using imipenem or meropenem disks. Zone Diameter ≤ 22 mm was defined as non-susceptible to the drugs.
Phenotypic AnalysisPhenotypic test for the CPMase-producing strains was conducted by using the modified Hodge test and the double-disk synergy test (imipenem/ imipenem+EDTA and meropenem/meropenem+ EDTA).
Antimicrobial Susceptibility TestingThe Minimal Inhibition Concentration (MIC) values for 15 antibiotics were determined by a broth microdilution method (BD Research Inc. USA). The antibiotics were as follows: ampicillin, cefazolin, cefotaxime, ceftazidime, cefepime, aztreonam, amoxicillin-clavulanic, piperacillin-tazobactam, imipenem, meropenem, trimethoprim-sulfamethoxazole, gentamicin, amikacin, ciprofloxacin, and colistin. The interpretive break points of Clinical and Laboratory Standards Institute (CLSI) M100-S24 were used to interpret the MIC results for antimicrobial agents[14]. The Escherichia coli ATCC25922 and K. pneumoniae ATCC BAA-1705 strains were adopted as the standards for quality control (QC). WHONET 5.6 software (http://www.whonet.org/) was used to perform resistance analysis.
Identification of CPMase-producing GenesTo detect CPMase-producing genes in the CPM-non-susceptible strains, PCR amplification was performed on a PTC-100-type PCR instrument (MJ Research Inc. USA). The CPMase-producing genes included blaIMP, blaVIM, blaSPM, blaGIM, blaNDM-1, blaSIM, blaKPC, blaGES, blaIMI/NMC-A, blaSME, and blaOXA, and the primers were shown in Table 1 [12, 15-17]. The reaction system (total volume, 50 µL) consisted of: PCR Master Mix (2 × PCR buffer, 3 mmol/L Mg2+, 200 µmol/L dNTPs, and 0.1 U Taq DNA polymerase), 50 pmol each of the two primers, and DNA template obtained by heating a bacterial suspension. The reaction conditions were as follows: pre-denaturation at 95 ℃ for 3 min, followed by 35 amplification cycles of 95 ℃ for 1 min, 55 ℃ for 1 min and 72 ℃ for 1 min, with a final extension step of 72 ℃ for 5 min.
|
Table 1 Primers used for PCR Amplification |
The PCR products from the above reactions were purified and sequenced using the ABI PRISM TM377 with the dideoxy-mediated chain-termination method. Sequences obtained were compared with the preexisting sequences via NCBI BLAST to determine the type of CPMase. The nucleotide sequence containing the blaIMP-4, blaIMP-8, blaNDM-1, and blaKPC-2 open reading frame has been assigned the EMBO/GenBank accession number FJ384365.1, EU368856.1, and KP036457.1 and KR108243.1.
Statistical AnalysisSPSS 12.0 was used to perform regression analysis. Trends of resistance rates to each antimicrobial agent for microorganisms were performed using Chi-square statistics. A P < 0.05 was considered statistically significant.
Results Clinical Features of CPM-non-susceptible K. pneumoniae StrainsDuring 2010-2014, 1, 730 non-duplicated strains of K. pneumoniae were isolated from different inpatients in our hospital. Among those strains, 179 (10.3%) were identified as non-susceptible (Zone Diameter ≤ 22 mm) to imipenem or meropenem via disk-diffusion method. The percentages of non-susceptible isolates were lower than 10% between 2010 and 2012, namely 7.8% (28/358) in 2010, 8.9% (37/415) in 2011, 7.4% (28/379) in 2012. However, it increased to 11.2% (40/356) in 2013 and further increased to 20.7% (46/222) in 2014.
The clinical features of CPM-non-susceptible K. pneumoniae isolates were shown in Table 2. The isolates were main obtained from Internal Medicine (39.7%, 71/179) and Haematology (29.6%, 53/179). Most of the patients were under 7 years old (76.0%, 136/179). The majority of the strains were isolated from tracheal aspirations (50.8%, 91/179) and blood (31.3%, 56/179). Notably, the isolates originated from blood increased from 14.2% to 41.3% during the study period.
|
|
Table 2 Clinical Features of the Carbapenemase-producing K. pneumoniae Strains |
Phenotypic analysis based on modified Hodge test and double-disk synergy test showed that none of CPM-non-susceptible isolates of K. pneumoniae had negative results in both tests, indicating all of the 179 isolates were CPMase producers. Among them, 152 (84.9%) strains were positive in the modified Hodge test and 174 (97.2%) positive in the double-disk synergy test.
The results of the disk-diffusion experiments showed that 156 (87.1%) of K. pneumoniae isolates were meropenem resistant, 122 (68.1%) exhibited imipenem resistance, and 120 (67.0%) were resistant to both imipenem and meropenem.
The results of broth microdilution experiments conducted for all of the 179 isolates were shown in Table 3. The isolates demonstrated very high resistance rates against ampicillin (100%), cefazolin (100%), cefotaxime (100%), amoxicillin-clavulanic (100%), and ceftazidime (99.4%). There were only two drugs with susceptibility rates higher than 50%, namely amikacin (88.2%) and ciprofloxacin (65.9%). An increase of resistance was seen for imipenem and meropenem from 14.3% to 89.1% and from 67.9% to 100%, respectively. No isolate of K. pneumoniae was found resistant to colistin.
|
|
Table 3 Antimicrobial Resistance Profiles of K. pneumoniae Strains during the Study Period |
The PCR results showed that 166 (92.7%) strains harbored the CPMase-producing genes detected in this study. The blaIMP and blaNDM-1genes were present in 95 (57.2%) and 65 (39.2%) strains, respectively, and the other 6 (3.6%) strains had blaKPCgene.
Subsequent sequencing of the 166 PCR-positive strains further identified the genotypes of the respective CPMase genes. Among the 95 strains harboring the blaIMP gene, 92 (96.8%) and 3 (3.2%) strains were IMP-4 and IMP-8 producers, respectively. The sequencing results also confirmed that the 65 strains with PCR positive results of blaNDM-1 gene were NDM-1 producers. In addition, all sequenced KPC producers (6 strains) had blaKPC-2 gene.
During our study period from 2010 to 2014, the most predominant CPMase-producing isolates were IMP-4 producers (51.4%, 92/179). NDM-1 producer also occupied a very large percentage (36.3%, 65/179). Only 3.4% (6/179) and 1.7% (3/179) were IMP-8 and KPC-2 producers, respectively. The annual distributions revealed an increase of NDM-1 producers and decrease of IMP-4 producers from 2010 to 2014 (Table 4).
|
|
Table 4 Distribution of Different Genotypes from 2010 to 2014 |
The results of broth microdilution experiments indicated that different CPMase producers had different profiles of antimicrobial resistance (Table 5). Compare to IMP-4 producers, the isolates from KPC-2 producers had higher resistant rates frequencies in terms of resistance to imipenem (P = 0.017), amikacin (P = 0.010) and ciprofloxacin (P= 0.013). There were also significant differences in the frequencies of drug resistance between the isolates from NDM-1 producers and IMP-4 producers for piperacillin-tazobactam (P = 0.000), imipenem (P = 0.000) and meropenem (P = 0.000). The isolates from KPC-2 producers and NDM-1 producers had significantly higher rates of drug resistance to antibiotics than those from the IMP-4 producers (P < 0.05).
|
|
Table 5 Antimicrobial Resistance Profiles of Different Genotypes of K. pneumoniae Strains |
As useful antimicrobial agents, the β-lactam antibiotics play an important role in treating infection in the pediatric population, in which, CPMs have the broadest spectrum and greatest stability against hydrolysis by β-lactamases[4]. CPMs have been regarded as a dependable drug for treating K. pneumoniae infections. However, with its increasing clinical usage, CPM-resistant K. pneumoniae are becoming more and more pervasive throughout the world[18], but few phenotypic and genotypic investigations on CPM-resistance K. pneumoniae has been reported in China[11-13]. This is the first study describing the 5-year prevalence of CPM-non-susceptible K. pneumoniae and their genetic characteristics responsible for CPMase production in a pediatric hospital in China.
Our study showed that the percentages of CPM-non-susceptible K. pneumoniae increased from 7.8% in 2010 to 20.7% in 2014 in our hospital. In addition, an increase in resistance was observed for imipenem and meropenem in our study, which is similar to the CHINET (antimicrobial resistance surveillance network in China) data[19]. Furthermore, we compared our data and the data from the children's hospitals in CHINET[20]. The increasing trend of drug resistant rates of imipenem and meropenem are similar, but the resistant rates against imipenem and meropenem varied in different hospitals and the rates in our hospital are higher than the others[20-22]. The possible interpretation for this difference is that patients in different hospitals have different clinical needs, which leads to different prescribing habits of doctors in different hospitals. Because most patients in our hospital have been treated in other hospital before and have limited antibiotic choices, imipenem and meropenem might be utilized more frequently in our hospital, resulting in higher resistant rates of these drugs.
The most common mechanism for CPM resistance is the production of CPMases. In recent years, there have been many reports of CPMase-producing K. pneumoniae worldwide and the main types of CPMases reported in Asia and Europeare are IMP, VIM, and NDM[9, 23-24]. Two genotypes, namely IMP-4 and IMP-8, are prevalent in China[25-26]. In our hospital, IMP-4 type K. pneumoniae was the predominant genotype from 2010 to 2012, but NDM-1 genotype became the predominant one in 2013 and 2014. NDM-1 type strains have been recently described and are calling more and more attentions because of its resistance to most antibiotics[27-29].
In the present study, the CPM-non-susceptible K. pneumoniae isolates showed a high rate of drug resistance to β-lactam antibiotics except aztreonam and piperacillin-tazobactam. It is worthwhile to note that 179 nosocomial K. pneumoniae isolates from selected pediatric departments have high rates of intermediate and resistance to CPM. The frequencies of resistance to imipenem and meropenem were 68.2% and 87.2%, and the rates of the intermediate to them were 26.8% and 8.4%, respectively. Therefore, it is suggested that imipenem and meropenem should be assessed at one time in order to find more CPM-non-susceptible K. pneumoniae. The CPM-non-susceptible K. pneumoniae isolates in our study showed the lowest resistance to amikacin (10.1%), followed by ciprofloxacin (20.7%), which may be due to these two drugs were rarely used in children because of their major side-effects.
In summary, the present study is generally to report on the characteristics of CPM-non-susceptible K. pneumoniae isolates from a pediatric hospital in China. The production of MBL, including two genotypes IMP and NDM, is one of the important mechanisms of CPM-non-susceptible of K. pneumoniae isolates in our pediatric setting. It is necessary to strengthen the surveillance of drug resistance and to gain an understanding of the characteristics and mechanisms of CPM-non-susceptible K. pneumoniae infections among the local pediatric population, which may help us better understand the prevalence of CPMase-producing K. pneumoniae and contribute to effective controls of the drug-resistant strains in pediatric clinics.
AcknowledgementsWe are grateful to all members of Beijing Children's Hospital for their cooperation and technical help.
Ethical StatementProtocol was approved by Ethics Committee of Beijing Children's Hospital, Capital Medical University. Informed consent was waived because we used existed strains and did not pose risk to patients.
| 1. | Struve C, Krogfelt K. Pathogenic potential of environmental Klebsiella pneumoniae isolates. Environ Microbiol, 2004, 6: 584–90. doi:10.1111/emi.2004.6.issue-6 |
| 2. | Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae:an Evolving Crisis of Global Dimensions. Clin Microbiol Rev, 2012, 25: 682–707. doi:10.1128/CMR.05035-11 |
| 3. | Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. P Natl Acad Sci USA, 2015, 112: E3574–81. doi:10.1073/pnas.1501049112 |
| 4. | van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant Enterobacteriaceae:a review of treatment and outcomes. Diagn Microbiol Infect Dis, 2013, 75: 115–20. doi:10.1016/j.diagmicrobio.2012.11.009 |
| 5. | Correa L, Martino M, Marra A, et al. 2013. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis, 2013; 13, 80. |
| 6. | Centers for Disease Control and Prevention (CDC). Vital signs:carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep, 2013, 62: 165–70. |
| 7. | Deshpande LM, Jones RN, Fritsche TR, et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae:Report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist, 2006, 12: 223–30. doi:10.1089/mdr.2006.12.223 |
| 8. | Chen L, Mathema B, Chavda KD, et al. Carbapenemase-producing Klebsiella pneumoniae:molecular and genetic decoding. Trends Microbiol, 2014, 22: 686–96. doi:10.1016/j.tim.2014.09.003 |
| 9. | Pitout JDD, Nordmann P, Poirel L. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. Antimicrob Agents Chemother, 2015, 59: 5873–84. doi:10.1128/AAC.01019-15 |
| 10. | Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis, 2011, 17: 1791–8. doi:10.3201/eid1710.110655 |
| 11. | Dai YY, Zhang CF, Ma XL, et al. Outbreak of carbapenemase-producing Klebsiella pneumoniae neurosurgical site infections associated with a contaminated shaving razor used for preoperative scalp shaving. Am J Infect Control, 2014, 42: 805–6. doi:10.1016/j.ajic.2014.03.023 |
| 12. | Liu Y, Wan LG, Deng Q, et al. First description of NDM-1-, KPC-2-, VIM-2-and IMP-4-producing Klebsiella pneumoniae strains in a single Chinese teaching hospital. Epidemiol Infect, 2015, 143: 376–84. doi:10.1017/S0950268814000995 |
| 13. | ZhouJ, Li GP, Ma XJ, et al. Outbreak of colonization by carbapenemase-producing Klebsiella pneumoniae in a neonatal intensive care unit:Investigation, control measures and assessment. Am J Infect Control, 2015, 43: 1122–4. doi:10.1016/j.ajic.2015.05.038 |
| 14. | Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement M100-S24. Wayne. Pennsylvania: CLSI, 2014. |
| 15. | Deshpande LM, Rhomberg PR, Sader HS, et al. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers:Report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis, 2006, 56: 367–72. doi:10.1016/j.diagmicrobio.2006.07.004 |
| 16. | NeilWoodford. Rapid characterization of beta-lactamases by multiplex PCR. Methods Mol Biol, 2010, 642: 181–92. doi:10.1007/978-1-60327-279-7 |
| 17. | Shanthi M, Sekar U, ArunagiriK, et al. OXA-181 Beta Lactamase is not a Major Mediator of Carbapenem Resistance in Enterobacteriaceae. J Clin Diagn Res, 2013, 7: 1986–8. |
| 18. | Ahmed-Bentley J, Chandran AU, Joffe AM, et al. Gram-Negative Bacteria That Produce Carbapenemases Causing Death Attributed to Recent Foreign Hospitalization. Antimicrob Agents Chemother, 2013, 57: 3085–91. doi:10.1128/AAC.00297-13 |
| 19. | Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect, 2016, 22: S9–S14. doi:10.1016/j.cmi.2016.01.001 |
| 20. | Hu FP, Zhu DM, Wang F, et al. CHINET surveillance of distribution and susceptibility of carbapenem-resistant Enterobacteriaceae isolates in 2012. Chinese Journal of Infection and Chemotherapy, 2014, 14: 382–6. |
| 21. | Meng JH, Zhu L, Li WL, et al. Antimicrobial resistance surveillance of gram-negative bacteria from children in China, 2012. Chin J Clin Pharmacol, 2015, 31: 990–2. |
| 22. | Jin Y, Shao CH, Li J, et al. Outbreak of Multidrug Resistant NDM-1-Producing Klebsiella pneumoniae from a Neonatal Unit in Shandong Province, China. PLoS One, 2015, 10: e0119571. doi:10.1371/journal.pone.0119571 |
| 23. | Centers for Disease Control and Prevention (CDC). Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States, 2010. MMWR Morb Mortal Wkly Rep, 2010, 59: 750. |
| 24. | Sánchez-Romero I, Asensio A, Oteo J, et al. Nosocomial Outbreak of VIM-1-Producing Klebsiella pneumoniae Isolates of Multilocus Sequence Type 15:Molecular Basis, Clinical Risk Factors, and Outcome. Antimicrob Agents Chemother, 2012, 56: 420–7. doi:10.1128/AAC.05036-11 |
| 25. | Chen LR, Zhou HW, Cai JC, et al. Combination of IMP-4 metallo-beta-lactamase production and porin deficiency causes carbapenem resistance in a Klebsiella oxytoca clinical isolate. Diagn Microbiol Infect Dis, 2009, 65: 163–7. doi:10.1016/j.diagmicrobio.2009.07.002 |
| 26. | Dong F, Song WQ, Xu XW, et al. Analysis of carbapenemase genotypes in carbapenem-nonsusceptible Enterobacteriaceae strains isolated from pediatric patient. Chinese Journal of Infection and Chemotherapy, 2013, 13: 270–4. |
| 27. | Bax BD, Chan PF, Eggleston DS, et al. Type ⅡA topoisomerase inhibition by a new class of antibacterial agents. Nature, 2010, 466: 935–40. doi:10.1038/nature09197 |
| 28. | Nordmann, Couard JP, Sansot D, et al. Emergence of an Autochthonous and Community-Acquired NDM-1-Producing Klebsiella pneumoniae in Europe. Clin Infect Dis, 2012, 54: 150–1. doi:10.1093/cid/cir720 |
| 29. | Yong D, TolemanMA, Giske CG, et al. Characterization of a New Metallo-beta-Lactamase Gene, bla(NDM-1), and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India. Antimicrob Agents Chemother, 2009, 53: 5046–54. doi:10.1128/AAC.00774-09 |